Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — ASX Small and Mid-Cap Conference 2020
15 slides from Anatara Lifesciences's conference presentation, Sep 8, 2020
Slide 1: ASX Release: Anatara Investor Presentation
ASX Release Anatara Investor Presentation MELBOURNE, 8 September 2020: Anatara Lifesciences (ASX: ANR) is pleased to release to investors a copy For personal use only of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small and Mid-Cap Conference 20
Slide 2: ASX Small and Mid-Cap Conference: Advancing gastrointestinal health
For personal use only ASX Small and Mid-Cap Conference 8 SEPTEMBER 2020 Advancing gastrointestinal health --------------------------- ASX: ANR
Slide 3: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 4: Key Investor Message
Key Investor Message For personal use only More than ever, the world is looking for safe and effective solutions to gut health. The Anatara team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans. 3
Slide 5: Corporate Fast Facts
Corporate Fast Facts Board of Directors: For personal use only Sue MacLeman ASX ticker code Dr Jane Ryan ANR Dr Tracie Ramsdale Dr David Brookes Management: Steve Lydeamore, CEO Dr Michael West, COO Share Price Market Capitalisation Product Development $0.19* $9.5 million* Advisory Board: Prof Peter
Slide 6: Investment highlights
Investment highlights For personal use only Human health asset, GaRP: • Aimed at restoring and maintaining gut health with excellent (pre-clinical in vitro and in vivo animal studies) data • Human clinical study initiation anticipated late 2020 • View to a partnering deal by end 2020 Animal health a
Slide 7: Irritable Bowel Syndrome
For personal use only Irritable Bowel Syndrome 6
Slide 8: About Irritable Bowel Syndrome (IBS)
About Irritable Bowel Syndrome (IBS) Region Prevalence Prevalence Prevalence For personal use only • IBS is a functional disorder. proportion; proportion; proportion; Incomplete knowledge of overall males females pathology, therefore the approach World 11.20% 10.47% 16.48% is symptom management Afri
Slide 9: Global consumer health market opportunity
Global consumer health market opportunity For personal use only Gastrointestinal supplements and OTC US $8 billion digestive remedies in USA alone 3,4 Probiotic supplements Other GI supplements OTC digestive supplements Align® (P&G) sales Iberogast® (Bayer) sales Buscopan® (Sanofi) sales (U.S.) 2018
Slide 10: Compelling Investment Case
Compelling Investment Case For personal use only Unmet need: limited pharmacological Intellectual treatment options; Property symptoms not well controlled6 Parallel licensing 60% demand for Strong pre- Prevalence: 11.2% discussions with complementary clinical data to of global global consumer popula
Slide 11: GaRP built on strong scientific foundations
GaRP built on strong scientific foundations For personal use only 10
Slide 12: Anatara's Unique Dietary Supplement - How does it work?
Small Intestine Anatara’s Unique Dietary Supplement - How does it work? For personal use only Small Intestine Colon Colon Correcting Alleviation of gut microbiota the Repair of gut to restore Reduction of symptomatic lining and normal inflammation diarrhoea barrier defects microbial associated with
Slide 13: GaRP has been shown to...
GaRP has been shown to….. • Address the dysbiosis of the microbiome For personal use only • Inhibiting the attachment and invasion of pro-inflammatory bacteria by >95% • Reduce gut inflammation • Reducing the production of pro-inflammatory proteins by >85% • Reducing colon inflammation and disrupted
Slide 14: Anticipated Company Milestones
Anticipated Company Milestones 2018 2018 2019 2019 2020 2020 2021 2021 H1 H2 H1 H2 H1 H2 H1 H2 For personal use only GaRP commercial feasibility Patent Application filed In vitro GaRP proof of concept - anti-inflammation - anti-attachment In vitro GaRP proof of concept - mucosal healing Ga
Slide 15: Contact Anatara Lifesciences Ltd
For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, Chief Executive Officer +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd 14
Anatara Lifesciences — ASX Small and Mid-Cap Conference 2020 on 6ix